Interim revenue was 4,453,648 thousand yen, up 8.5% year-over-year. Operating income was 468,211 thousand yen, ordinary income was 485,739 thousand yen, and interim net income was 321,252 thousand yen. Dividend forecast was revised. Full-year forecast is revised down to revenue 1,030 hundred million yen, operating income 1,100 million yen, and net income 770 million yen, but a recent announcement on dividend increase has been made. Share buybacks continue, and the equity ratio rose to 85.4%.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"6678","jir_company_name":"Techno Medica Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-11-06","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/11\/6678-20261106-01.pdf","jir_short_summary":"Interim revenue was 4,453,648 thousand yen, up 8.5% year-over-year. Operating income was 468,211 thousand yen, ordinary income was 485,739 thousand yen, and interim net income was 321,252 thousand yen. Dividend forecast was revised. Full-year forecast is revised down to revenue 1,030 hundred million yen, operating income 1,100 million yen, and net income 770 million yen, but a recent announcement on dividend increase has been made. Share buybacks continue, and the equity ratio rose to 85.4%.","jir_summary":"### Overview of Results\nFor the cumulative second quarter period, revenue increased 8.5% year-over-year to 4,453,648 thousand yen, supported by expanded domestic demand for blood collection tube preparation devices and systems. Meanwhile, the ratio of overseas sales declined, and gross profit rose to 2,155,645 thousand yen, with operating income increasing significantly to 468,211 thousand yen. Cost control and stabilization of selling, general and administrative expenses contributed to the results. Interim net income increased 58.2% year-over-year to 321,252 thousand yen. The financial summary includes supplementary materials and a scheduled results briefing.\n\n### Shareholder Returns and Financial Stability\nThe equity ratio remains high at 85.4%, and attention should be paid to the announced revision to the dividend forecast (dividend increase). An increase in year-end treasury stock has affected the capital structure. Cash and cash equivalents decreased to 8,438 million yen, but operating cash flow has improved due to a decrease in accounts receivable, among other factors. Ongoing dividend policy and utilization of treasury stock will remain focal points.","jir_financial_highlights":"Revenue: 4,453,648 thousand yen (Up 8.5% year-over-year)\nOperating Income: 468,211 thousand yen (Up 75.7% year-over-year)\nOrdinary Income: 485,739 thousand yen (Up 65.0% year-over-year)\nInterim Net Income: 321,252 thousand yen (Up 58.2% year-over-year)\nTotal Assets: 15,491,603 thousand yen (Decrease from end of previous fiscal year)\nEquity Ratio: 85.4% (Up 5.2 percentage points from end of previous fiscal year)\nTreasury Stock: 5,154,174 thousand yen (Increase from end of prior interim period)","jir_category":"","jir_hashtags":"#TechnoMedica, #InterimResults, #ShareBuyback","jir_key_figures":"Revenue: 4,453,648 thousand yen (Up 8.5% year-over-year)\nOperating Income: 468,211 thousand yen (Up 75.7% year-over-year)\nInterim Net Income: 321,252 thousand yen (Up 58.2% year-over-year)","jir_meta_title":"Techno Medica Co., Ltd. \u2013 Key Points from FY2027 Second Quarter Interim Results | Interim Profit Growth and Dividend Revision","jir_meta_description":"Techno Medica Co., Ltd.'s FY2027 second quarter interim results: revenue 4,453,648 thousand yen, operating income 468,211 thousand yen, interim net income 321,252 thousand yen, significantly above prior year. Equity ratio 85.4% and a revised dividend forecast (increase) announced. Monitor future performance outlook and capital policy.","jir_og_title":"Techno Medica Co., Ltd. Posts Strong Interim Profit Growth\uff5cAnnounces Dividend Revision","jir_og_description":"Techno Medica Co., Ltd.'s interim results: revenue 4,453,648 thousand yen, operating income 468,211 thousand yen, net income 321,252 thousand yen. Dividend revision announced; equity ratio remains above 84%. Focus on outlook.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[{\"jir_chart_id\": \"revenue_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Revenue Trend\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Prior Year\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Revenue\\\",\\\"data\\\":[4453.648],\\\"borderColor\\\":\\\"#3e95cd\\\",\\\"fill\\\":false}]},\\\"options\\\":{}}\"}, {\"jir_chart_id\": \"operating_profit_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Operating Income Trend\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Prior Year\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Operating Income\\\",\\\"data\\\":[468.211],\\\"borderColor\\\":\\\"#8e5ea2\\\",\\\"fill\\\":false}]},\\\"options\\\":{}}\"}, {\"jir_chart_id\": \"net_profit_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Interim Net Income Trend\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Prior Year\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Interim Net Income\\\",\\\"data\\\":[321.252],\\\"borderColor\\\":\\\"#3cba9f\\\",\\\"fill\\\":false}]},\\\"options\\\":{}}\"}, {\"jir_chart_id\": \"segment_revenue_breakdown\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Segment Revenue Breakdown\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Blood Collection Tube Preparation Devices & Systems\\\",\\\"Specimen Testing Devices\\\",\\\"Consumables, etc.\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Revenue\\\",\\\"data\\\":[1344.345,246.476,2862.826],\\\"backgroundColor\\\":[\\\"#3e95cd\\\",\\\"#8e5ea2\\\",\\\"#3cba9f\\\"]}]},\\\"options\\\":{}}\"}, {\"jir_chart_id\": \"margin_analysis\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Gross Profit and Operating Income Margins\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Interim\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Gross Profit\\\",\\\"data\\\":[2155.645],\\\"backgroundColor\\\":\\\"#e8c3b9\\\"},{\\\"label\\\":\\\"Operating Income\\\",\\\"data\\\":[468.211],\\\"backgroundColor\\\":\\\"#f0a6a6\\\"}]},\\\"options\\\":{}}\"}, {\"jir_chart_id\": \"guidance_comparison\", \"jir_chart_type\": \"table\", \"jir_chart_title\": \"Full-Year Guidance vs Actuals\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"table\\\",\\\"data\\\":{\\\"headers\\\":[\\\"Metric\\\",\\\"Full-Year Forecast\\\",\\\"Actual\\\"],\\\"rows\\\":[[\\\"Revenue\\\",\\\"10,300\\\",\\\"4,453.648 (Interim)\\\"]]},\\\"options\\\":{}}\"}]","ir_related_company":57947,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-144100","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n